Headlines about Cellect Biotechnology (NASDAQ:APOP) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellect Biotechnology earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.2555701764265 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
NASDAQ:APOP traded up $0.18 during trading on Friday, hitting $6.38. The company had a trading volume of 19,586 shares, compared to its average volume of 22,992. The stock has a market capitalization of $34.71, a PE ratio of -4.37 and a beta of 4.70. Cellect Biotechnology has a 1-year low of $6.12 and a 1-year high of $13.50.
A number of research analysts have recently commented on APOP shares. Zacks Investment Research raised shares of Cellect Biotechnology from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, March 20th. ValuEngine cut shares of Cellect Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, HC Wainwright set a $14.00 target price on shares of Cellect Biotechnology and gave the stock a “buy” rating in a research report on Friday, January 5th.
Cellect Biotechnology Company Profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.